Direct AMPK Activation Extends Animal Lifespan by Over 25 Percent

Direct Enzyme Activation Lengthens Lifespan in Lab Models

Scientists have extended the lifespan of several animal species by more than 25 percent using a compound that targets a master metabolic regulator. The study was published in the journal Aging Cell by researchers at the Medical Research Council Laboratory of Medical Sciences (MRC LMS), Imperial College London, the University of Cologne, and partner institutions. The team tested the direct activator compound, known as 991, across three laboratory model organisms: fission yeast, nematode worms, and fruit flies.

Each of these model organisms showed extended survival after receiving the compound. Nematode worms typically live for three weeks in laboratory settings, while fruit flies survive for roughly three months. These short lifespans allowed the research teams to observe survival outcomes faster than would be possible in mammalian models such as mice, which live approximately three years.

How the AMPK Energy Sensor Regulates Cellular Fuel

Adenosine monophosphate-activated protein kinase (AMPK) serves as an internal fuel gauge that monitors cellular energy in real time. When cellular energy drops during fasting, physical exercise, or physiological stress, the enzyme switches off energy-intensive processes. These halted tasks include synthesizing new proteins and storing fat tissue.

At the same time, the activated enzyme turns on metabolic pathways that generate fuel from stored reserves. It directs cells to burn existing fat and circulating glucose for immediate energy. Disruptions in this control system contribute to common metabolic conditions, including type 2 diabetes and obesity.

Differences Between Direct and Indirect Activators

Metabolic researchers already study several common drugs that stimulate this cellular sensor through indirect pathways. The type 2 diabetes medication metformin and the weight-management drug semaglutide both increase enzyme activity through secondary metabolic actions. These indirect effects make it difficult for laboratory scientists to determine whether health changes stem solely from the enzyme or from unrelated cellular mechanisms.

The investigative team used compound 991 to bypass intermediate biochemical steps and stimulate the enzyme binding site directly. According to the study authors, direct stimulation produces a cleaner experimental result with fewer off-target actions. Direct activators of this enzyme have already demonstrated safety in human clinical trials focused on specific metabolic diseases.

Preclinical Limits and the Research Timeline for Mammals

The survival increases observed in this study occurred strictly in non-mammalian laboratory models. Yeast, worms, and flies share ancient metabolic pathways with mammals, but their organ systems differ substantially from human physiology. Because of these biological differences, findings from invertebrate survival studies cannot be directly applied to human health decisions.

The research teams plan to evaluate whether compound 991 can improve metabolic health markers and prolong life in mice before considering broader applications. Formal anti-aging clinical trials in humans face additional regulatory hurdles because regulatory bodies do not classify aging itself as a disease. People interested in supporting metabolic balance should discuss established lifestyle strategies and approved therapies with their personal clinician instead of seeking experimental compounds.